Elizabeth Czerepak

Chief Financial Officer

Ms. Czerepak has over 30years of experience in big pharma, biotechnology and venture capital. At Merck & Co., Hoffmann-La Roche and BASF Pharma she held leadership positions in finance and business development, including playing a key role in the Roche $5.4B acquisition of Syntex and the $6.9B sale of BASF to Abbott. Later, Ms. Czerepak was a Managing Director at JPMorgan and Bear Stearns, while serving as a General Partner of the BSHI venture fund. At BSHI, she led investments in thirteen biotech companies and served on six of the boards. She and her partners helped raise hundreds of millions of dollars for the portfolio and achieved most exits through IPO and acquisition. Most recently, Ms. Czerepak has served as CFO of four biotech companies, including two start-ups, Isarna Therapeutics and Genevant Sciences, and two which she took public, Cancer Genetics, Inc. (NASDAQ: CGIX) and Altimmune, Inc. (NASDAQ: ALT).

Ms. Czerepak currently serves on the Board of Directors of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), DelCath Systems Inc. (NASDAQ:DCTH) and Scilex Pharmaceuticals.

Ms. Czerepak holds an MBA from Rutgers University and a B.A. magna cum laude from Marshall University. She was a FINRA (previously NASD) Series 7 and Series 63 Registered Representative from 2001 to 2008. Ms. Czerepak recently earned a Corporate Director Certificate from Harvard Business School.

© 2020 BeyondSpring Inc. All rights reserved.